US regulators should require NAION warnings on GLP-1 drug labels

The EMA added a NAION warning to semaglutide labels in 2025, while US labels for Ozempic and Wegovy still carry no such warning.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

The Trump administration announced 100% tariffs on brand-name drugs with carveouts for certain categories

Medical marijuana was reclassified as Schedule III in a historic federal policy shift

Multiple former FDA officials described a mass exodus following Trump administration cuts to the agency

FTC reached a settlement with CVS over PBM insulin price manipulation practices

The FDA should regulate health-tracking smart rings as medical devices — debated regarding consumer wellness devices versus medical oversight scope

Boston Scientific and McKesson were hit by cyberattacks exposing vulnerabilities in healthcare data security

The Justice Department prosecuted over half a billion dollars in healthcare and COVID fraud schemes

The FDA moved to close the GRAS loophole allowing food additives without federal notification

Walmart settled a federal opioid lawsuit with the Justice Department

100% tariffs on imported medicines will lower domestic drug prices without causing shortages — debated regarding trade policy impact on pharmaceutical supply chains

Insurers should be barred from setting premiums using genetic tests

More young people need to get their brain scanned

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2